FibroGen to Present at Oppenheimer Rare Disease Summit on December 11
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Source: Newsfilter
- Executive Participation: FibroGen's CEO Thane Wettig will participate in a panel at the Rare Disease Summit on December 11 in New York, showcasing the company's potential catalysts in the rare disease space, aimed at attracting investor attention and enhancing market awareness.
- One-on-One Meetings: The management team will offer one-on-one investor meetings during the conference, designed to strengthen connections with potential investors and drive positive stock performance through direct engagement.
- Product Development Progress: FibroGen's Roxadustat is approved in Europe and Japan for treating anemia in chronic kidney disease patients, demonstrating the company's innovative capabilities and market potential in the biopharmaceutical sector.
- Clinical Trial Plans: The company is evaluating the Phase 3 trial plan for Roxadustat in the U.S. for lower-risk myelodysplastic syndrome, which, if successful, will further solidify its leadership position in the anemia treatment market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
